AI Meets Olfaction: SpotitEarly Unveils LUCID 2.0, Scaling Early Cancer Detection to Millions

ENGLEWOOD, N.J.--(BUSINESS WIRE)--SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today unveiled LUCID 2.0, the next generation of its Bio-AI Hybrid platform, designed to scale the company's breath-based cancer screening technology for clinical use. Built for large-scale diagnostics, the platform combines bio-olfactory detection, a multi-modal sensor array, and a proprietary deep-learning AI architecture, with the capacity to process up to 1.73 million tests per year per screening center.

For decades, dogs have been proven to possess an extraordinary natural ability to sniff out cancer, yet harnessing that gift at a global scale has remained an elusive goal. LUCID 2.0 bridges this gap by turning detection dogs into highly advanced biological sensors. Powered by proprietary hardware and an array of sensors spread across the screening room that passively capture hundreds of sub-second physiological and behavioral signals during their natural search, LUCID translates what the dogs sense into data that science can measure. By using advanced AI to analyze this unique dataset and make the final diagnostic decision, SpotitEarly effectively transforms natural instinct into clinical intelligence, creating a highly accurate, scalable, and measurable tool for mass early detection.

Yet, as many cancer detection ventures have discovered, capturing powerful biological data is only half the battle; the true hurdle lies in converting those breakthroughs into scalable, error-free clinical workflows. Moving seamlessly from a patient’s breath sample to a physician-signed result requires navigating an intricate chain of hardware steps, sample handoffs, and strict quality controls. Without an automated infrastructure, even the most revolutionary diagnostic science cannot scale to meet global demand.

To solve this, SpotitEarly designed LUCID 2.0 to function as a unified operating system, seamlessly integrating five interconnected components on a single platform: cloud architecture, advanced AI analysis, facility management, specialized canine screening hardware, and an intuitive patient-facing app. The result is a fully closed-loop workflow that automates every stage of the cycle from the moment a patient orders a kit on their phone, to the digital delivery of a physician-signed result right back to that same device.

At the heart of LUCID 2.0 is a multi-model AI system that monitors and analyzes each canine in real time, leveraging continuous data streams from video, audio, and motion sensors integrated into each screening port. When a detection dog encounters cancer-related volatile organic compounds (VOCs), it exhibits distinct behavioral and physiological patterns. Many of these micro-signals are completely invisible to the human eye, often occurring before the dog even consciously registers the scent. Capturing thousands of data points per sniff, the platform converts each sample into a 0-to-100 confidence score reflecting the likelihood of a positive signature. This architecture, where the canine acts as the biological sensor and the AI serves as the definitive decision-maker, unlocks true global scale. Because the cloud-based AI carries the diagnostic weight, any authorized facility worldwide deploying LUCID hardware can instantly transform into a high-throughput early detection hub.

"LUCID 2.0 is what allows our science to operate as a real medical platform at clinical scale," said Shlomi Madar, PhD, CEO of SpotitEarly. "There is a growing body of peer-reviewed literature demonstrating the ability of dogs to sniff cancer. Our platform is the first one to operationalize that science into a reproducible end-to-end process that patients and clinicians can trust. And, every test processed through the platform expands our proprietary dataset, making it more powerful and differentiated over time, something no competitor will be able to replicate without years of clinical operation.”

LUCID 2.0 builds on the clinical foundation SpotitEarly established through its prospective, double-blind clinical study of more than 1,300 participants, published in Scientific Reports, which demonstrated an overall sensitivity of 94% across the four most common cancers: breast, lungs, colorectal, and prostate cancers. The company is currently advancing two additional clinical trials: the PINK Study, a 2,000-participant multicenter, double-blind observational study focused on breast cancer detection with Hackensack Meridian Health; and a multi-year investigator-initiated lung cancer clinical trial with Temple Health’s Fox Chase Cancer Center.

To learn more about LUCID 2.0 and how SpotitEarly is industrializing early cancer detection, visit www.spotitearly.com.

About SpotitEarly

SpotitEarly aims to revolutionize cancer screening with its breath-based early detection test for multiple types of cancer. Powered by LUCID, a proprietary bio-AI hybrid platform, the test will integrate advanced artificial intelligence with nature's unparalleled detection abilities to identify cancer-associated volatile organic compounds (VOCs) at early stages. By combining AI with the scent-based biometrics of trained canines, SpotitEarly will introduce a simple breath collection process involving a face mask kit. A diverse, multidisciplinary team of medical professionals, scientists, and technology experts collaborate seamlessly to bring this innovative solution to life. Subject to regulatory approval, SpotitEarly aims to improve access to cancer screening, enhance early detection rates, and significantly boost survival outcomes. For more information, visit our website or follow SpotitEarly on LinkedIn, Facebook, and Instagram.